GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Praxis Precision Medicines Inc (NAS:PRAX) » Definitions » Quick Ratio

Praxis Precision Medicines (Praxis Precision Medicines) Quick Ratio : 5.39 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Praxis Precision Medicines Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Praxis Precision Medicines's quick ratio for the quarter that ended in Dec. 2023 was 5.39.

Praxis Precision Medicines has a quick ratio of 5.39. It generally indicates good short-term financial strength.

The historical rank and industry rank for Praxis Precision Medicines's Quick Ratio or its related term are showing as below:

PRAX' s Quick Ratio Range Over the Past 10 Years
Min: 3.23   Med: 6.03   Max: 19.23
Current: 5.39

During the past 6 years, Praxis Precision Medicines's highest Quick Ratio was 19.23. The lowest was 3.23. And the median was 6.03.

PRAX's Quick Ratio is ranked better than
64.84% of 1553 companies
in the Biotechnology industry
Industry Median: 3.53 vs PRAX: 5.39

Praxis Precision Medicines Quick Ratio Historical Data

The historical data trend for Praxis Precision Medicines's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Praxis Precision Medicines Quick Ratio Chart

Praxis Precision Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial 6.67 19.23 7.48 3.23 5.39

Praxis Precision Medicines Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 3.16 5.31 6.15 5.39

Competitive Comparison of Praxis Precision Medicines's Quick Ratio

For the Biotechnology subindustry, Praxis Precision Medicines's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Praxis Precision Medicines's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Praxis Precision Medicines's Quick Ratio falls into.



Praxis Precision Medicines Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Praxis Precision Medicines's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(84.88-0)/15.749
=5.39

Praxis Precision Medicines's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(84.88-0)/15.749
=5.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Praxis Precision Medicines  (NAS:PRAX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Praxis Precision Medicines Quick Ratio Related Terms

Thank you for viewing the detailed overview of Praxis Precision Medicines's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Praxis Precision Medicines (Praxis Precision Medicines) Business Description

Traded in Other Exchanges
N/A
Address
99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Executives
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Marcio Souza officer: Chief Executive Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Dean J Mitchell director C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Timothy Edwin Kelly officer: Chief Financial Officer C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Lauren Mastrocola officer: Principal Accounting Officer C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Alex Nemiroff officer: General Counsel and Secretary C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bsof Parallel Master Fund L.p. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Merit Ester Cudkowicz director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Jeffrey Chodakewitz director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Stefan Vitorovic director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Blackstone Holdings I/ii Gp L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
William D Young director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Group Management L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154

Praxis Precision Medicines (Praxis Precision Medicines) Headlines